Gene therapy and genome editing for primary immunodeficiency diseases

In past two decades the gene therapy using genetic modified autologous hematopoietic stem cells (HSCs) transduced with the viral vector has become a promising alternative option for treating primary immunodeficiency diseases (PIDs). Despite of some pitfalls at early stage clinical trials, the field...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhi-Yong, Thrasher, Adrian J., Zhang, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chongqing Medical University 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063425/
https://www.ncbi.nlm.nih.gov/pubmed/32181274
http://dx.doi.org/10.1016/j.gendis.2019.07.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063425/
https://www.ncbi.nlm.nih.gov/pubmed/32181274
http://dx.doi.org/10.1016/j.gendis.2019.07.007

Ejemplares similares